Skip to main content

Recombinant Mouse CD19 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9730-CD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
9730-CD-050

Key Product Details

Source

CHO

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

N-terminal Sequence Analysis

Arg19 and Ser68

Predicted Molecular Mass

57 kDa

SDS-PAGE

78-95 kDa, reducing conditions

Reviewed Applications

Read 2 reviews rated 5 using 9730-CD in the following applications:

Formulation, Preparation and Storage

9730-CD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Background: CD19

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.

References

  1. Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
  2. Tedder, T.F. et al. (1997) Immunity 6:107.
  3. Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
  4. Rickert, R.C. et al. (1995) Nature 376:352.
  5. Engel, P. et al. (1995) Immunity 3:39.
  6. Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
  7. Deaglio, S. et al. (2007) Blood 109:5390.
  8. Bradbury, L. et al. (1992) J. Immunol. 149:2841.
  9. Krop, I. et al. (1996) J. Immunol. 157:48.
  10. O'Rourke, L.M. et al. (1998) Immunity 8:635.
  11. Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
  12. Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
  13. Carter, R.H. and D.T. Fearon (1992) Science 256:105.

Alternate Names

CD19, CVID3, Leu-12

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Gene Symbol

CD19

UniProt

Additional CD19 Products

Product Documents for Recombinant Mouse CD19 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse CD19 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...